Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

September 30, 2024 / 2024 Power 25 Health Care

2024 Power 25 Health Care: Vlad Coric

Vlad Coric
Click here to go back to the 2024 Power 25 Health Care home page
More Information

Vlad Coric has led one of Connecticut’s most successful homegrown bioscience companies.

Under Coric’s leadership, Biohaven Pharmaceuticals’ blockbuster migraine drug Nurtec ODT became a top-prescribed migraine medicine in its class in the United States.

The New Haven-based company launched Nurtec ODT, its first commercial product, in 2020, after winning U.S. Food and Drug Administration approval.

The drug’s popularity drew the eyes of Big Pharma, and in October 2022, Pfizer Inc. acquired Biohaven for $11.6 billion in cash, a deal that Coric said would expand distribution of the company’s migraine drugs.

But Coric didn’t just take his newfound riches and go home. Instead, after the Pfizer deal was complete, he launched a newly independent clinical-stage company in New Haven called Biohaven Ltd., which has been working on a pipeline of experimental medicines for a range of neurological disorders.

Biohaven’s growth has allowed the company to expand its presence in New Haven. In 2022, Biohaven bought the 42,000-square-foot former landmark Quinnipiack Club at Church and Orange streets for $4.1 million. And in May of this year, the company purchased 209 Church St. for $2.35 million, an 8,900-square-foot building located near Biohaven’s headquarters, at 215 Church St.

Coric has been well-received by Wall Street. He’s made appearances on well-known CNBC personality Jim Cramer’s “Mad Money” show.

Coric has decades of drug discovery and clinical development experience, including at the Yale School of Medicine and Bristol-Myers Squibb.

He earned his medical degree from the Wake Forest University School of Medicine, and a bachelor’s degree in neurobiology and physiology at the University of Connecticut.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF